Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Current Liabilities (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Total Current Liabilities for 12 consecutive years, with $76.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 179.67% to $76.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.7 million through Dec 2025, up 179.67% year-over-year, with the annual reading at $76.7 million for FY2025, 179.67% up from the prior year.
  • Total Current Liabilities hit $76.7 million in Q4 2025 for Viking Therapeutics, up from $26.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $76.7 million in Q4 2025 to a low of $8.8 million in Q4 2021.
  • Historically, Total Current Liabilities has averaged $21.7 million across 5 years, with a median of $17.4 million in 2023.
  • Biggest YoY gain for Total Current Liabilities was 179.67% in 2025; the steepest drop was 40.28% in 2025.
  • Year by year, Total Current Liabilities stood at $8.8 million in 2021, then skyrocketed by 150.02% to $21.9 million in 2022, then decreased by 12.81% to $19.1 million in 2023, then soared by 43.26% to $27.4 million in 2024, then skyrocketed by 179.67% to $76.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for VKTX at $76.7 million in Q4 2025, $26.1 million in Q3 2025, and $32.0 million in Q2 2025.